Remove trial restrictions Start for $1

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
Baxter
Express Scripts
Johnson and Johnson
Medtronic

Last Updated: May 17, 2022

Allergan Holdings Company Profile


✉ Email this page to a colleague

« Back to Dashboard

Summary for Allergan Holdings
International Patents:129
US Patents:18
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Allergan Holdings

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan Holdings VIBERZI eluxadoline TABLET;ORAL 206940-002 May 27, 2015 RX Yes Yes 8,691,860 See Plans and Pricing Y See Plans and Pricing
Allergan Holdings VIBERZI eluxadoline TABLET;ORAL 206940-001 May 27, 2015 RX Yes No 9,205,076 See Plans and Pricing See Plans and Pricing
Allergan Holdings VIBERZI eluxadoline TABLET;ORAL 206940-001 May 27, 2015 RX Yes No 8,691,860 See Plans and Pricing Y See Plans and Pricing
Allergan Holdings VIBERZI eluxadoline TABLET;ORAL 206940-001 May 27, 2015 RX Yes No 9,364,489 See Plans and Pricing See Plans and Pricing
Allergan Holdings VIBERZI eluxadoline TABLET;ORAL 206940-002 May 27, 2015 RX Yes Yes 8,772,325 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for Allergan Holdings Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1725537 PA2017005,C1725537 Lithuania See Plans and Pricing PRODUCT NAME: ELUKSADOLINAS ARBA JO FARMACINIU POZIURIU PRIIMTINAS ENANTIOMERAS, DIASTEREOMERAS, RACEMATAS ARBA DRUSKA; REGISTRATION NO/DATE: EU/1/16/1126 20160919
1725537 10/2017 Austria See Plans and Pricing PRODUCT NAME: ELUXADOLIN ODER EIN PHARMAZEUTISCH ANNEHMBARES ENANTIOMER, DIASTEREOMER, RACEMAT ODER SALZ DAVON; REGISTRATION NO/DATE: EU/1/16/1126 (MITTEILUNG) 20160921
1725537 PA2017005 Lithuania See Plans and Pricing PRODUCT NAME: ELUKSADOLINAS ARBA JO FARMACINIU POZIURIU PRIIMTINAS ENANTIOMERAS, DIASTEREOMERAS, RACEMATAS ARBA DRUSKA; REGISTRATION NO/DATE: EU/1/16/1126 20160919
1725537 132017000028006 Italy See Plans and Pricing PRODUCT NAME: ELUXADOLINE O UN ENANTIOMERO, DIASTEREOMERO, RACEMATO FARMACEUTICAMENTE ACCETTABILE O SALI DELLO STESSO(TRUBERZI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1126, 20160921
1725537 122017000009 Germany See Plans and Pricing PRODUCT NAME: ELUXADOLIN ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/16/1126 20160919
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
AstraZeneca
Mallinckrodt
McKinsey
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.